News | August 05, 2024
Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
